Mantle cell lymphoma remains incurable, despite researchers’ best efforts. However, new treatment options show promise in the relapsed/refractory setting and may improve patient outcomes if moved to the front-line, according to Dr. Reem Karmali.
Dr. Reem Karmali
Advertisement
Articles by Dr. Reem Karmali
Maintenance therapy with Imbruvica appeared to be a feasible option for patients with mantle cell lymphoma, according to Dr. Reem Karmali.
Advertisement
Latest Updated Articles
Imbruvica Shows Promise as Maintenance Therapy for Patients With MCLPublished: June 13th 2019 | Updated:
- Targeted Therapies for Advanced MCL May Improve Outcomes as Front-line Treatment
Published: June 26th 2019 | Updated:
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma
2
11 Years Living With Stage 4 Cancer Inspires Gratitude and Reflection
3
Every FDA Oncology Approval From November 2025
4
What Patients Should Know About EGFR Mutated Lung Cancer Treatment
5
